Pilar Nava-Parada

549 total citations
14 papers, 286 citations indexed

About

Pilar Nava-Parada is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pilar Nava-Parada has authored 14 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Genetics and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pilar Nava-Parada's work include Chronic Lymphocytic Leukemia Research (6 papers), CAR-T cell therapy research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Pilar Nava-Parada is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), CAR-T cell therapy research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Pilar Nava-Parada collaborates with scholars based in United States, Spain and France. Pilar Nava-Parada's co-authors include Larry R. Pease, Keith L. Knutson, Esteban Celis, Guido Forni, Leisha A. Emens, Scott M. Lippman, Salma Alam, Faye M. Johnson, Robin L. Jones and Andrew Stephens and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Pilar Nava-Parada

13 papers receiving 277 citations

Peers

Pilar Nava-Parada
MY Hsieh Taiwan
Gabriel Prolla Brazil
Scott Selby United States
Keiichi Iwanami Japan
Manfred Ahlgrimm Germany
Indu Raman United States
Pasquale L. Fedele Australia
Saïda Aarrass Netherlands
Eleonora Zanetti Italy
Elaine Wiegert United States
MY Hsieh Taiwan
Pilar Nava-Parada
Citations per year, relative to Pilar Nava-Parada Pilar Nava-Parada (= 1×) peers MY Hsieh

Countries citing papers authored by Pilar Nava-Parada

Since Specialization
Citations

This map shows the geographic impact of Pilar Nava-Parada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pilar Nava-Parada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pilar Nava-Parada more than expected).

Fields of papers citing papers by Pilar Nava-Parada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pilar Nava-Parada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pilar Nava-Parada. The network helps show where Pilar Nava-Parada may publish in the future.

Co-authorship network of co-authors of Pilar Nava-Parada

This figure shows the co-authorship network connecting the top 25 collaborators of Pilar Nava-Parada. A scholar is included among the top collaborators of Pilar Nava-Parada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pilar Nava-Parada. Pilar Nava-Parada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
El-Khoueiry, Anthony B., Daniel J. Olson, Jacob Thomas, et al.. (2023). AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose-escalation study.. JCO Global Oncology. 9(Supplement_1). 26–26. 3 indexed citations
2.
El-Khoueiry, Anthony B., Se‐Hoon Lee, Jacob Thomas, et al.. (2023). Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort.. Journal of Clinical Oncology. 41(16_suppl). 2533–2533. 8 indexed citations
3.
Hintzen, Gabriele, Susanne Wingert, Pilar Nava-Parada, et al.. (2022). 729 Targeting epidermal growth factor receptor (EGFR)-expressing solid tumors with AFM24, a novel CD16A bispecific innate cell engager: comprehensive correlative science findings from a phase 1 study. Regular and Young Investigator Award Abstracts. A762–A762.
4.
El-Khoueiry, Anthony B., et al.. (2022). The combination of CD16A/EGFR innate cell engager, AFM24, with SNK01 autologous natural killer cells in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2675–TPS2675. 2 indexed citations
5.
Nastoupil, Loretta J., et al.. (2021). Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs. 35(4). 459–468. 10 indexed citations
6.
Nava-Parada, Pilar, Ahmed Shelbaya, & Chadi Nabhan. (2020). Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. Future Oncology. 16(26). 2017–2027. 13 indexed citations
7.
Falchi, Lorenzo, Alessandra Ferrajoli, Ira Jacobs, & Pilar Nava-Parada. (2018). An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(8). 508–518.e14. 10 indexed citations
8.
Brown, Jennifer R., Florence Cymbalista, Jeff P. Sharman, et al.. (2017). The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. The Oncologist. 23(3). 288–296. 14 indexed citations
9.
Jones, Robin L., Edward S. Kim, Pilar Nava-Parada, et al.. (2014). Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clinical Cancer Research. 21(4). 693–700. 77 indexed citations
10.
Brown, Jennifer R., Wael A. Harb, Brian T. Hill, et al.. (2013). Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 122(21). 1630–1630. 39 indexed citations
11.
Pierce, Daniel W., Sabine Ponader, Kumudha Balakrishnan, et al.. (2013). Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292. Blood. 122(21). 4169–4169. 1 indexed citations
12.
Nava-Parada, Pilar, Guido Forni, Keith L. Knutson, Larry R. Pease, & Esteban Celis. (2007). Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors. Cancer Research. 67(3). 1326–1334. 85 indexed citations
13.
Nava-Parada, Pilar & Leisha A. Emens. (2007). GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.. PubMed. 9(5). 490–7. 22 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MY Hsieh Breakdown of academic impact, for papers by Gabriel Prolla Breakdown of academic impact, for papers by Scott Selby Breakdown of academic impact, for papers by Keiichi Iwanami Breakdown of academic impact, for papers by Manfred Ahlgrimm Breakdown of academic impact, for papers by Indu Raman Breakdown of academic impact, for papers by Pasquale L. Fedele Breakdown of academic impact, for papers by Saïda Aarrass Breakdown of academic impact, for papers by Eleonora Zanetti Breakdown of academic impact, for papers by Elaine Wiegert
Rankless by CCL
2026